Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.59 USD | +2.57% | -1.25% | -50.70% |
04-18 | Deutsche Bank Cuts Price Target on 10x Genomics to $55 From $60, Keeps Buy Rating | MT |
03-26 | 10x Genomics, Inc. Commercially Launches Visium HD Spatial Gene Expression Assay | CI |
Sales 2024 * | 678M 54.23B | Sales 2025 * | 790M 63.18B | Capitalization | 3.3B 264B |
---|---|---|---|---|---|
Net income 2024 * | -188M -15.04B | Net income 2025 * | -114M -9.12B | EV / Sales 2024 * | 4.4 x |
Net cash position 2024 * | 324M 25.9B | Net cash position 2025 * | 366M 29.3B | EV / Sales 2025 * | 3.72 x |
P/E ratio 2024 * |
-17.4
x | P/E ratio 2025 * |
-29.8
x | Employees | 1,259 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.5% |
Latest transcript on 10x Genomics, Inc.
1 day | +2.57% | ||
1 week | -1.25% | ||
Current month | -26.49% | ||
1 month | -26.49% | ||
3 months | -36.16% | ||
6 months | -24.22% | ||
Current year | -50.70% |
Managers | Title | Age | Since |
---|---|---|---|
Serge Saxonov
FOU | Founder | 47 | 01/07/12 |
Ben Hindson
FOU | Founder | 49 | 01/07/12 |
Justin McAnear
DFI | Director of Finance/CFO | 49 | 30/09/18 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Stuelpnagel
CHM | Chairman | 66 | 31/07/13 |
Kim Popovits
BRD | Director/Board Member | 65 | 25/03/20 |
Mathai Mammen
BRD | Director/Board Member | 57 | 22/08/17 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 27.59 | +2.57% | 1,337,623 |
25/04/24 | 26.9 | -2.25% | 1,133,268 |
24/04/24 | 27.52 | -0.22% | 1,800,383 |
23/04/24 | 27.58 | -0.79% | 1,991,587 |
22/04/24 | 27.8 | -0.50% | 1,792,088 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-50.70% | 3.3B | |
+0.89% | 12.8B | |
-10.29% | 7.61B | |
-1.16% | 4.51B | |
+5.74% | 4.49B | |
+12.21% | 2.73B | |
-16.13% | 2.02B | |
-11.50% | 1.73B | |
-5.02% | 1.64B | |
-8.80% | 1.53B |
- Stock Market
- Equities
- TXG Stock